Biotechnology

#Biotechnology #Drug discovery #Events #Innovation #SLAS2023

DDW launches event podcast series for SLAS2023

Ahead of this year’s SLAS2023 conference in San Diego (which takes place 25 February – 1 March), DDW’s Megan Thomas narrates articles from the DDW SLAS2023 supplement as part of the DDW Events podcast series. This is episode one, A Welcome to SLAS 2023,… Read More

#News

#Antibody #Antibody-based therapeutics #Biotechnology #Drug development #Drug discovery #Genomics #Single-cell analysis

Using single-cell technology to create human antibody-based therapeutics

San Francisco-based biotechnology company Infinimmune is emerging from stealth with its $12 million seed financing. The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human… Read More

#Business & Investment #Exclusive Content

#Assays #Biotechnology #DNA #Next generation sequencing #Research

Key acquisition for next generation sequencing research assays

Integrated DNA Technologies has purchased next generation sequencing (NGS) research assays from Invitae Corporation under the trademarked name Archer.   The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with a solution to uncover biomarkers and… Read More

#News

#Biobanking #Biotechnology #Research

UK biobank offers regenerative medicine research potential  

BioGrad, a company offering medical and scientific support for education and research organisations, is to open the UK's second largest biobank facility in Liverpool, as part of a £7.6m investment into a new headquarters at Wavertree Technology Park.  In collaboration with the University of Leicester, BioGrad biobank has already welcomed… Read More

#Business & Investment #News

#Biotechnology #Disease networks #Drug targets #Financing #Investment #Precision medicine #Start-ups

New biotech aspires to reveal insights into disease biology

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative… Read More

#News #Start-up Zone

#Biologics #Biotechnology #Funding #Seed funding #Therapeutics

How will $41 million be used to fight chronic and age-related diseases? 

Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics… Read More

#Business & Investment #News

#Biotechnology #Collaboration #Drug targets #Therapeutics

Collaboration to stabilise a challenging drug target  

Swedish biotech company Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.  The collaboration brings together Salipro Biotech’s services in developing stable antigens of GPCRs, ion channels and transporters via its proprietary… Read More

#News

Synthetic DNA
#AI #Antibodies #Biotechnology #Drug development #Drug discovery #Synthetic biology #Synthetic DNA #Synthetic libraries

Synthetic biology tools advancing and accelerating drug discovery efforts

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery.  The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. It has made its… Read More

#Exclusive Content

#Biotechnology #Drug development #Drug discovery #Genomics #Synthetic biology #Synthetic DNA

Synthetic biology: Shaping the future of drug discovery 

By Lu Rahman  There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research reports… Read More

#Exclusive Content #Trends & Analysis

Genomics
#Biotechnology #Comment #Data #Gene editing #Genetics / genomics #Genome sequencing #Healthcare #Public health #Research #Whole genome sequencing

Why genomic healthcare data matters in the development of new therapies 

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies - precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact.  The origins  One might argue that this all started… Read More

#Exclusive Content #Opinion #Trends & Analysis

AI brain
#AI / data analytics / healthtech / informatics #ALS #Biotechnology #Clinical trials #Drug discovery #Genomics

AI-driven biotech initiates Phase I trial for ALS drug 

Verge Genomics, a clinical-stage, tech-enabled biotechnology company using artificial intelligence (AI) and human data to transform drug discovery, has announced today that the first subject has been dosed in a Phase I clinical trial of VRG50635 for amyotrophic lateral sclerosis (ALS).  VRG50635 is a small molecule inhibitor… Read More

#News

#Biotechnology #Drug discovery #Life sciences #Pharmacology

What’s interesting about Australian drug discovery? 

Australia’s drug discovery industry shows promise and innovation, as well as business opportunities. DDW’s Megan Thomas takes a look at some of the reasons why we should be keeping an interested eye on the developments coming out of this country.   The Sector Snapshot 2022: Expansion is continuous   The Sector Snapshot… Read More

#Exclusive Content #Market Reports #Trends & Analysis

#Biotechnology #Data #Precision medicine #Webinar

Webinar offers an insider’s view on computational drug discovery  

Collaborative Drug Discovery (CDD) is hosting a webinar in which CDD’s Eric Gifford speaks with two industry experts, Dr Josh Horan and Dr Michael Kappler about their experience working with data at biotech companies.   The live webinar will take place on December 1, 2022 at 8AM (PT), 11AM… Read More

#News

#Biotechnology #Clinical trial #Liver disease

Clinical study first step towards treating respiratory syncytial virus 

Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).  Context … Read More

#News

mRNA vaccines
#Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #mRNA #Vaccines

Preparing for new-era drug modalities with technology 

Listen to this article on the DDW podcast: Samsung Biologics’ Senior Vice President, James Park, explores the opportunities emerging for CDMOs to support mRNA developers as they explore new therapeutic areas for patients.  Prior to the pandemic, messenger RNA (mRNA) drug development was niche and predominantly pointed at different disease targets,… Read More

#Exclusive Content

#Biotechnology #Data #Immunology / Virology & Vaccines #In Silico Biology

Sekkei Bio implements system to centralise research data 

Sekkei Bio, an India-based company dedicated to building technologies for drug and vaccine design with global impact, has implemented CDD Vault as the main platform to house its research data.   Sekkei Bio has made progress toward finding therapies for diabetes and pain, and has a management team… Read More

#News